Nicotine patch claims are one quarter of 1997 OTC/supplement NAD reviews.
This article was originally published in The Tan Sheet
Executive SummaryNICOTINE REPLACEMENT PATCHES GENERATE A QUARTER OF NAD REVIEWS involving OTC drugs, dietary supplements and infant formulas in 1997. The National Advertising Division of the Council of Better Business Bureaus completed 16 OTC, supplement and formula cases during the year, of which four were smoking cessation patch products -- two for McNeil Consumer Product's Nicotrol and two for SmithKline Beecham's NicoDerm CQ. The number of OTC/supplement/formula cases is down 30% from 1996, when NAD completed 23 reviews, reflecting lower 1997 NAD totals in general due to limited resources and a smaller staff, as well as NAD's concentration on new product categories such as the telecommunications industry
You may also be interested in...
Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further.
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.